Applying randomised trials to the real world: A VOYAGER of discovery

Graeme K Ambler; Rafia Latif; Chris P Twine

doi:10.1016/j.ejvs.2021.10.025

Applying randomised trials to the real world: A VOYAGER of discovery

Graeme K Ambler^*, Rafia Latif, Chris P Twine

^*Corresponding author for this work

Bristol Medical School (PHS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

2 Citations (Scopus)

65 Downloads (Pure)

Abstract

The choice of antithrombotic therapy for patients undergoing intervention for peripheral arterial diseases is complex, with different antithrombotics appearing to be the best option for different patient groups. The COMPASS and VOYAGER trials aimed to simplify these decisions. While COMPASS examined patients with stable peripheral arterial disease, VOYAGER examined patients undergoing intervention. The headline findings were similar in that “dual pathway inhibition” with aspirin and low dose rivaroxaban reduced the primary endpoint (a composite of limb and cardiovascular events), at the cost of increased major bleeding events. The trials were intended to be pragmatic, with broad inclusion criteria so that antithrombotic prescribing could be simplified to a single treatment strategy.

Original language	English
Pages (from-to)	295
Number of pages	1
Journal	European Journal of Vascular and Endovascular Surgery
Volume	63
Issue number	2
Early online date	29 Nov 2021
DOIs	https://doi.org/10.1016/j.ejvs.2021.10.025
Publication status	Published - 1 Feb 2022

Access to Document

10.1016/j.ejvs.2021.10.025

Full-text PDF (accepted author manuscript)
This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at 10.1016/j.ejvs.2021.10.025. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 119 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{517e21283ae74ab28f547e0e534eed2b,

title = "Applying randomised trials to the real world: A VOYAGER of discovery",

abstract = "The choice of antithrombotic therapy for patients undergoing intervention for peripheral arterial diseases is complex, with different antithrombotics appearing to be the best option for different patient groups. The COMPASS and VOYAGER trials aimed to simplify these decisions. While COMPASS examined patients with stable peripheral arterial disease, VOYAGER examined patients undergoing intervention. The headline findings were similar in that “dual pathway inhibition” with aspirin and low dose rivaroxaban reduced the primary endpoint (a composite of limb and cardiovascular events), at the cost of increased major bleeding events. The trials were intended to be pragmatic, with broad inclusion criteria so that antithrombotic prescribing could be simplified to a single treatment strategy.",

author = "Ambler, {Graeme K} and Rafia Latif and Twine, {Chris P}",

year = "2022",

month = feb,

day = "1",

doi = "10.1016/j.ejvs.2021.10.025",

language = "English",

volume = "63",

pages = "295",

journal = "European Journal of Vascular and Endovascular Surgery",

issn = "1078-5884",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - Applying randomised trials to the real world

T2 - A VOYAGER of discovery

AU - Ambler, Graeme K

AU - Latif, Rafia

AU - Twine, Chris P

PY - 2022/2/1

Y1 - 2022/2/1

N2 - The choice of antithrombotic therapy for patients undergoing intervention for peripheral arterial diseases is complex, with different antithrombotics appearing to be the best option for different patient groups. The COMPASS and VOYAGER trials aimed to simplify these decisions. While COMPASS examined patients with stable peripheral arterial disease, VOYAGER examined patients undergoing intervention. The headline findings were similar in that “dual pathway inhibition” with aspirin and low dose rivaroxaban reduced the primary endpoint (a composite of limb and cardiovascular events), at the cost of increased major bleeding events. The trials were intended to be pragmatic, with broad inclusion criteria so that antithrombotic prescribing could be simplified to a single treatment strategy.

AB - The choice of antithrombotic therapy for patients undergoing intervention for peripheral arterial diseases is complex, with different antithrombotics appearing to be the best option for different patient groups. The COMPASS and VOYAGER trials aimed to simplify these decisions. While COMPASS examined patients with stable peripheral arterial disease, VOYAGER examined patients undergoing intervention. The headline findings were similar in that “dual pathway inhibition” with aspirin and low dose rivaroxaban reduced the primary endpoint (a composite of limb and cardiovascular events), at the cost of increased major bleeding events. The trials were intended to be pragmatic, with broad inclusion criteria so that antithrombotic prescribing could be simplified to a single treatment strategy.

U2 - 10.1016/j.ejvs.2021.10.025

DO - 10.1016/j.ejvs.2021.10.025

M3 - Article (Academic Journal)

C2 - 34857448

SN - 1078-5884

VL - 63

SP - 295

JO - European Journal of Vascular and Endovascular Surgery

JF - European Journal of Vascular and Endovascular Surgery

IS - 2

ER -

Applying randomised trials to the real world: A VOYAGER of discovery

Abstract

Access to Document

Handle.net

Fingerprint

Cite this